Dorthe Yakymenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dorthe Yakymenko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Norgaard
Department of Section for Transfusion Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
1 shared publication- Amabelia Rodrigues
Bandim Health Project, Indepth Network , Bissau, Guinea-Bissau
1 shared publication - Ane Bærent Fisker
Bandim Health Project, Indepth Network Bissau Guinea‐Bissau
1 shared publication - Birgitte Rode Diness
Bandim Health Project, Indepth Network, Apartado 861, Bissau, Guinea-Bissau
1 shared publication - Cesario Martins
Bandim Health Project, Indepth network, Bissau, Guinea-Bissau
1 shared publication - Christine Stabell Benn
Bandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau; Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark
1 shared publication
Latest Publications
- 29 June 2017
- Published by Wiley in Transfusion Medicine
- Vol. 28 (3) , 208-215
Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy
SUMMARY: Objectives: The primary objective of this feasibility study was to identify quality of life (QoL) scores and symptom scales as tools for measuring patient‐reported outcomes (PRO) associated with haemoglobin level in chemotherapy‐treated cancer patients. Secondary objectives included comparing QoL and symptoms between randomisation arms.Background: Anaemia in cancer patients undergoing chemotherapy is associated with decreased QoL. One treatment option is red blood cell transfusion (RBCT). However, the optimal haemoglobin trigger for transfusion is unknown.Methods: Patients were randomised to a haemoglobin trigger for RBCT of either < 9·7 g dL−1 (arm A) or < lower normal level, female: 11·5 g dL−1, male: 13·1 g dL−1 (arm B). Four PROs were used: Functional Assessment of Cancer Therapy‐General (FACT‐G) and the FACT‐Anaemia (FACT‐An), a Numeric Rating Scale on symptoms of anaemia and self‐reported Performance Status (PS). The association between haemoglobin and PRO variables was assessed using a linear mixed model with random effects.Results: A total of 133 patients were enrolled, of which 86 patients received RBCT (28 in arm A, 58 in arm B). Baseline questionnaires were filled out in 79·7% of cases. Haemoglobin levels were significantly correlated with FACT‐An, FACT‐An Total Outcome Index (TOI), Functional Well‐Being, fatigue and PS. Improvement on several PRO variables was observed in both arms after RBCT, with clinically minimal important differences observed in FACT‐G, Physical Well‐Being, FACT‐An, FACT‐An TOI, fatigue and dyspnoea.Conclusions: QoL scores of physical and functional domains as well as self‐reported anaemia‐related symptoms correlated well with haemoglobin level in chemotherapy‐treated cancer patients.
- 29 June 2017
- Published by Wiley in Transfusion Medicine
- Vol. 28 (3) , 208-215
Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy
SUMMARY: Objectives: The primary objective of this feasibility study was to identify quality of life (QoL) scores and symptom scales as tools for measuring patient‐reported outcomes (PRO) associated with haemoglobin level in chemotherapy‐treated cancer patients. Secondary objectives included comparing QoL and symptoms between randomisation arms.Background: Anaemia in cancer patients undergoing chemotherapy is associated with decreased QoL. One treatment option is red blood cell transfusion (RBCT). However, the optimal haemoglobin trigger for transfusion is unknown.Methods: Patients were randomised to a haemoglobin trigger for RBCT of either < 9·7 g dL−1 (arm A) or < lower normal level, female: 11·5 g dL−1, male: 13·1 g dL−1 (arm B). Four PROs were used: Functional Assessment of Cancer Therapy‐General (FACT‐G) and the FACT‐Anaemia (FACT‐An), a Numeric Rating Scale on symptoms of anaemia and self‐reported Performance Status (PS). The association between haemoglobin and PRO variables was assessed using a linear mixed model with random effects.Results: A total of 133 patients were enrolled, of which 86 patients received RBCT (28 in arm A, 58 in arm B). Baseline questionnaires were filled out in 79·7% of cases. Haemoglobin levels were significantly correlated with FACT‐An, FACT‐An Total Outcome Index (TOI), Functional Well‐Being, fatigue and PS. Improvement on several PRO variables was observed in both arms after RBCT, with clinically minimal important differences observed in FACT‐G, Physical Well‐Being, FACT‐An, FACT‐An TOI, fatigue and dyspnoea.Conclusions: QoL scores of physical and functional domains as well as self‐reported anaemia‐related symptoms correlated well with haemoglobin level in chemotherapy‐treated cancer patients.
- Open Access
- 1 September 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 77
The impact of different doses of vitamin A supplementation on male and female mortality. A randomised trial from Guinea-Bissau
Vitamin A supplementation (VAS) given to children between 6 months and 5 years of age is known to reduce mortality in low-income countries. We have previously observed that girls benefit more from a lower dose of VAS than the one recommended by WHO, the effect being strongest if diphtheria-tetanus-pertussis vaccine (DTP) was the most recent vaccination. We aimed to test these observations.
- 1 September 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 77
Open AccessThe impact of different doses of vitamin A supplementation on male and female mortality. A randomised trial from Guinea-Bissau
Vitamin A supplementation (VAS) given to children between 6 months and 5 years of age is known to reduce mortality in low-income countries. We have previously observed that girls benefit more from a lower dose of VAS than the one recommended by WHO, the effect being strongest if diphtheria-tetanus-pertussis vaccine (DTP) was the most recent vaccination. We aimed to test these observations.